HomeNewsPress ReleaseCarl Hvass appointed Chief Financial Officer

Carl Hvass appointed Chief Financial Officer.

  • Published 08/06/2022
  • Categories Press Release
  • Download Download

8th June 2022. Bionical Emas, a global Contract Research Organisation (CRO) providing services to the pharmaceutical and biotech sectors, has appointed Carl Hvass as its Chief Financial Officer (CFO).

Carl brings with him a wealth of experience after having held senior finance positions for most of his career, most recently within the CRO industry as Group Financial Controller at Ergomed Plc and before this at Chiltern International Limited.

Carl will be responsible for the financial function across Bionical Emas, which includes cash flow management, assessing and strengthening the financial controls and overseeing all aspects of the Group’s financial success, reporting into CEO, Jonathan Waring-Hughes. He joins the Executive Leadership Team.

Carl is a Fellow of the Institute of Chartered Accountants in England and Wales (ICAEW).

We are delighted to welcome Carl to the company as we move through to the next phase of our exciting growth and expansion. He brings a wealth of sector-specific knowledge and experience having held senior financial positions at various PE backed and AIM listed CRO’s.

Carl’s deep understanding of the clinical research sector will enable us to improve our financial modelling and forecasting for future success, as well as ensuring we are well positioned to fund our future growth strategies.

Jonathan Waring-Hughes, Chief Executive Officer at Bionical Emas

Contact details

Bionical Emas
Katie Clayton, Head of Marketing
+44 (0) 1462 416435

Meare Consulting
Adrian Duffield, Managing Director
+44 (0) 7990 85 85 48

Note to Editors

Bionical Emas (bionicalemas.com) is a Contract Research Organisation (CRO) which combines Clinical Development, Early Access Program (EAP) and Clinical Trial Supply (CTS) services to deliver a unique, seamless approach to pioneering the way life-changing medicines are developed and accessed for patients around the world.

The Group deliver full clinical development services to global pharma and biotech companies. It’s integrated suite of services enables Bionical Emas to maximize access, collect data and generate evidence at every point along the drug development pathway.

Bionical Emas runs global programs, employs 250 people, and has offices in US, Europe, and Australia. It serves 10 of the top 25 pharma companies.

How can we support you?

Our dedicated teams of experts are on hand to help should you require any additional resource or further information about our services.

COVID-19 Guidance & Measures

A statement from the Bionical Emas Group on guidance & measures regarding COVID-19 - read here

In relation to staff and visitor safety, we have full risk assessments in place for all of our workplaces. These risk assessments are revisited and updated regularly, to reflect changing risks, knowledge and circumstances, and to reflect evolving Government guidance. We have not placed the risk assessments here on the website as they would become out of date too quickly. However, you are welcome to email info@bionical-emas.com to request access to our most up to date risk assessments applicable to your needs. Please note that all our staff are notified of all applicable risk assessments and updates, along with ‘quick guides’ automatically via our e-learning system.